
KTTA Stock Forecast & Price Target
KTTA Analyst Ratings
Bulls say
Pasithea Therapeutics is a promising biotechnology company focused on developing treatments for a range of CNS disorders and diseases. Their innovative approach, particularly with the development of next-generation MEK inhibitor PAS-004, shows potential for success in both the orphan and oncology market. With strong clinical data so far and a clear strategy for future growth and development, the company's stock has a positive outlook and potential for significant upward movement in the future.
Bears say
Pasithea Therapeutics is facing major challenges ahead with a conservative approach to valuation and potential competition in the market. Their focused research may not be enough in a highly competitive market, and risk factors such as failed clinical trials or lack of funding could impede the company's progress.
This aggregate rating is based on analysts' research of Pasithea Therapeutics Corp and is not a guaranteed prediction by Public.com or investment advice.
KTTA Analyst Forecast & Price Prediction
Start investing in KTTA
Order type
Buy in
Order amount
Est. shares
0 shares